Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-8040 plus consolidation therapy in AML (Phase II, double-blind, placebo-controlled)
2014-002702-21Phase 2Suspended
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Mar 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing BL-8040 + consolidation therapy with Placebo + consolidation therapy (2 arms). Primary endpoint: Relapse-free survival. Started Mar 2015; status: suspended.
02
Drugs
motixafortide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-002702-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002702-21.